Pasithea Therapeutics (KTTA) News Today $0.77 0.00 (-0.26%) As of 11:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KTTA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients5 hours ago | globenewswire.comPasithea announces enrollment of cohort 2 in Phase 1/1b trial of PAS-004September 8, 2025 | msn.comPasithea Therapeutics Receives Recommendation to Escalate Phase 1/1b Trial of PAS-004 to 8mg Dose LevelSeptember 8, 2025 | quiverquant.comQPasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment ConferenceAugust 29, 2025 | globenewswire.comPasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceAugust 28, 2025 | markets.businessinsider.comPasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsJuly 31, 2025 | globenewswire.comKTTA Pasithea Therapeutics Corp. - Seeking AlphaJuly 25, 2025 | seekingalpha.comPasithea Therapeutics schedules 2025 annual meeting for September 3July 13, 2025 | investing.comPasithea Therapeutics Appoints Dr. James Lee to Scientific Advisory Board to Advance PAS-004 Development for Inflammatory DiseasesJune 12, 2025 | nasdaq.comPasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory BoardJune 11, 2025 | globenewswire.comPasithea Therapeutics Reports Promising Interim Results for PAS-004 in Phase 1 Trial for Refractory Solid Tumors at ASCO 2025June 4, 2025 | nasdaq.comPasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025June 2, 2025 | globenewswire.comPasithea Therapeutics Reports Promising Preclinical Data for PAS-004 as a Novel MEK Inhibitor for Inflammatory DiseasesMay 21, 2025 | nasdaq.comPasithea Announces Strong Preclinical Results For PAS-004 In Inflammatory Disease ModelMay 21, 2025 | nasdaq.comPasithea Therapeutics Stock Draws Retail Buzz As Early Data Shows Potential In Treating Inflammatory DiseasesMay 21, 2025 | msn.comPasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market DiseasesMay 20, 2025 | globenewswire.comPasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial SiteMay 14, 2025 | globenewswire.comPasithea Therapeutics Closes $5 Million Public Offering to Advance Development of PAS-004 for Neurofibromatosis and Cancer IndicationsMay 9, 2025 | nasdaq.comPasithea Therapeutics Announces Closing of $5 Million Public OfferingMay 7, 2025 | finance.yahoo.comPasithea Therapeutics Raises $6.3 Million in Stock OfferingMay 7, 2025 | tipranks.comPasithea Therapeutics Announces Closing of $5 Million Public OfferingMay 7, 2025 | globenewswire.comPasithea Therapeutics Announces Pricing of $5 Million Public OfferingMay 6, 2025 | finance.yahoo.comPasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s ElatedMay 6, 2025 | msn.comPasithea Therapeutics Announces Pricing of $5 Million Public OfferingMay 6, 2025 | globenewswire.comPasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial ResultsMay 6, 2025 | benzinga.comPasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004May 6, 2025 | globenewswire.comPasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer PatientsApril 29, 2025 | globenewswire.comPasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual MeetingApril 24, 2025 | globenewswire.comPasithea Reports Positive Safety Review Committee Recommendation From Phase 1 Study Of PAS-004April 11, 2025 | nasdaq.comPasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing CohortApril 11, 2025 | msn.comPasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerApril 10, 2025 | globenewswire.comPasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer ConferenceMarch 24, 2025 | finance.yahoo.comKTTA stock touches 52-week low at $1.32 amid market challengesFebruary 12, 2025 | msn.comPasithea Therapeutics Shares Rise After Positive Safety Review for Cancer TreatmentFebruary 6, 2025 | marketwatch.comPasithea announces Safety Review Committee recommendationFebruary 6, 2025 | markets.businessinsider.comBig Mid-Week Move From This Small BiotechFebruary 6, 2025 | msn.comPasithea's PAS-004 advances in cancer trial with no toxicitiesFebruary 6, 2025 | msn.comPasithea Therapeutics Advances PAS-004 Clinical Trial to Next Dose Level Following Safety Review Committee RecommendationFebruary 5, 2025 | quiverquant.comQPasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerFebruary 5, 2025 | globenewswire.comKTTA stock touches 52-week low at $2.19 amid market challengesJanuary 31, 2025 | msn.comPasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4January 14, 2025 | globenewswire.comPasithea Therapeutics announces SRC recommended proceeding to cohort 4November 20, 2024 | markets.businessinsider.comPasithea Therapeutics Advances PAS-004 Clinical Trial to Next Dose Level Following Positive Safety Review FindingsNovember 20, 2024 | quiverquant.comQPasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerNovember 20, 2024 | globenewswire.comCrude Oil Down Over 2%; US Initial Jobless Claims FallSeptember 27, 2024 | msn.comDow Surges Over 250 Points; Accenture Earnings Top ViewsSeptember 27, 2024 | benzinga.comPasithea Therapeutics Shares Move Higher After Positive Data for Cancer TreatmentSeptember 26, 2024 | marketwatch.comPasithea Announces Positive Initial Data From Phase 1 Trial Of PAS-004 In Advanced Cancer; Stock UpSeptember 26, 2024 | markets.businessinsider.comPasithea Therapeutics (NASDAQ:KTTA) Stock Quotes, Forecast and News SummarySeptember 26, 2024 | benzinga.comPasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq RulesSeptember 26, 2024 | globenewswire.com Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KTTA Media Mentions By Week KTTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KTTA News Sentiment▼0.450.92▲Average Medical News Sentiment KTTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KTTA Articles This Week▼31▲KTTA Articles Average Week Get the Latest News and Ratings for KTTA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Pasithea Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Promis Neurosciences News Sonnet BioTherapeutics News Passage Bio News Synergy CHC News Q32 Bio News Natural Alternatives International News Citius Pharmaceuticals News Aytu BioPharma News Lexaria Bioscience News Cingulate News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KTTA) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredSean Hannity: Help Protect Your RetirementThis Guide to retirement protection has helped thousands protect over $3 billion dollars in retirement savings...Goldco Precious Metals | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KTTA Stock Alerts